Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Zhejiang Provincial Science and Technology Cooperation Center Conference (July 2020)
17 slides from Optiscan Imaging's conference presentation, Jul 3, 2020

Slide 1: Optiscan Presentation
ASX Announcement 3 July 2020 Optiscan Presentation Optiscan Imaging Limited (ASX: OIL, Optiscan) provides a copy of the attached presentation from the Zhejiang Provincial Science and Technology Cooperation Center Conference. For and on behalf of Optiscan Imaging Limited: Darren Lurie Executive Chair

Slide 2: Optiscan Imaging Ltd (ASX:OIL)
Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection

Slide 3: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 30 June 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may r

Slide 4: Notice
Notice Not an offer or financial productadvice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure docu

Slide 5: Corporate Snapshot
Corporate Snapshot Board Total Securities on Issue Darren Lurie – Executive Chairman ▪ 477,778,800 Ordinary Shares B.LLB (Hons) and B.COM(Hons) ▪ 25,600,000 unlisted options Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia)

Slide 6: OPTISCAN Introduction - Technology
OPTISCAN Introduction - Technology 4.7 mm Optiscan Technology diameter • Successful Development of hand-held Confocal Microscope for Medical and Research Imaging • World-leading and Patent Protected Technology • Real-time “Virtual Biopsy”, visualisation of human living tissue • Capture all Cancer Ce

Slide 7: Clinical Confocal Laser Endomicroscopy Applications
Clinical Confocal Laser Endomicroscopy Applications Clinical Applications and Devices: • Oral Cancer - InVivage® • Breast Cancer - InVivage® • Neurosurgery – CONVIVO® (Carl Zeiss Meditec Co-operation) Pre-clinical Device: FIVE2 (ViewVivo®) Cancer research, Tissue regeneration, Cell tracking, Photody

Slide 8: Oral Cancer Diagnosis, Survival Rates and Economic Cost
Oral Cancer Diagnosis, Survival Rates and Economic Cost 80 – 90 % Five Year Treatment cost for Early diagnosis Survival Rate1 Patients diagnosed with Stage 4 Oral Cancer are 2.5x more than patients 57% Five Year for diagnosed with Late diagnosis Stage 12 Survival Rate1 “need to investigate novel tec

Slide 9: New InVivage User Interface Designed for Doctors
New InVivage® User Interface Designed for Doctors Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)

Slide 10: OPTISCAN – Oral Cancer FY2020 Progress
OPTISCAN – Oral Cancer FY2020 Progress 3 Oral Cancer Studies and Trials: • Memorial Sloan Kettering Cancer Centre in New York (“MSK”) (on-going) • Melbourne Dental School in collaboration with Peter MacCallum Cancer Centre, Royal Melbourne Hospital, MSK and Australian Centre for Oral Oncology Resear

Slide 11: Chinese Dental Market Growth
Chinese Dental Market Growth Total Number of Dental Care Delivery Organisations KPPMG. (2016). Commercial opportunities in the dental care market in china. https://assets.kpmg/content/dam/kpmg/cn/pdf/en/2016/10/commercial-opportunities-in-the-dental-care-market-in-china.pdf

Slide 12: Dental Market Size - China
Dental Market Size - China • China: 48 Public Tertiary Dental Hospitals • Guangdong Province: 158 Stomatology Departments in General Hospitals, 14 Public and Private Dental Hospitals KPMG. (2016). Commercial opportunities in the dental care market in china. https://assets.kpmg/content/dam/kpmg/cn/pd

Slide 13: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women 2.1 8.5% 2.5 Million Million 2.1 million new cases of 8.5% of all new cancer In 2021, the total number breast cancer predicted in cases in China are breast of existing breast cancer 2018 (globally) 1 cancer 2 patients in China will be 2.5 million3 ▪ Since

Slide 14: Optiscan - Breast Cancer Surgery
Optiscan - Breast Cancer Surgery Intraoperative Assessment of Breast Cancer Surgical Margin Normal Breast Tissue • Goal: Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin. • Benefits: Reduce risk of residual tumour, need for repeat surgery, patient e

Slide 15: ZEISS CONVIVO – Carl Zeiss Meditec Co-operation
ZEISS CONVIVO® – CARL ZEISS MEDITEC (CZM) CO-OPERATION ZEISS CONVIVO® 297,000 • Target Application: Tumour margin detection in Brain Brain and CNS Cancer surgery cancer cases • FDA 510(k) Clearance and CE Mark obtained for p.a. CONVIVO® worldwide • Zeiss is an international leader in optics and opto

Slide 16: Distributor Strategy for China Pre-Clinical Market
Distributor Strategy for China Pre-Clinical Market • New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China. ▪ South and West China: Guangzhou Yunxing (Purple andBlue) ▪ East China: Biotimes Technology Limited (Green) ▪ North China: To be Advised

Slide 17: Clinical and Research Imaging Platform Technology
Clinical and Research Imaging Platform Technology Brain ENT Airways Esophagus Pleura Stomach Breast Small bowel Pancreas Liver Cartilage Colon Tendons Ovary Bladder Cervix Prostate
Source: company website
More decks from Optiscan Imaging Limited
Bell Potter Healthcare Conference (November 2026)11 slides · Nov 17, 2026
Investor Presentation (December 2025)37 slides · Dec 4, 2025
Shareholder Meeting (November 2025)40 slides · Nov 14, 2025
ASX SMIDcaps Conference, Sydney 202522 slides · Sep 24, 2025
Corporate Update (April 2025)26 slides · Apr 10, 2025
TSN ASX Gems Conference (March 2025)16 slides · Mar 28, 2025